Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry.
about
Autonomic Dysregulation in Multiple SclerosisNeurogenic bowel dysfunction in patients with spinal cord injury, myelomeningocele, multiple sclerosis and Parkinson's diseaseSecondary and tertiary treatments for multiple sclerosis patients with urinary symptomsThe Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigueDevelopment of a short form and scoring algorithm from the validated actionable bladder symptom screening tool.Health-related quality of life and economic impact of urinary incontinence due to detrusor overactivity associated with a neurologic condition: a systematic reviewLower urinary tract symptom prevalence and management among patients with multiple sclerosisTablet-based screening improves continence management in multiple sclerosisPrevalence of stress urinary incontinence in women with multiple sclerosis.Validation of a Dutch version of the Actionable 8-item screening questionnaire for neurogenic bladder overactivity in multiple sclerosis: an observational web-based studyHealth insurance affects the use of disease-modifying therapy in multiple sclerosis.The prevalence of urinary catheterization in women and men with multiple sclerosis.Overactive bladder symptoms in patients with multiple sclerosis: Frequency, severity, diagnosis and treatment.Development and validation of the actionable bladder symptom screening tool for multiple sclerosis patientsBotulinum neurotoxin-A treatment of lower urinary tract symptoms in multiple sclerosis.Urinary catheterization may not adversely impact quality of life in multiple sclerosis patientsPelvic floor disorders and multiple sclerosis: are patients satisfied with their care?Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis.Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder.Management of neurogenic lower urinary tract dysfunction in multiple sclerosis patients.Botulinum Toxin Treatment in Multiple Sclerosis-a Review.Management of neurogenic bladder in patients with multiple sclerosis.Bladder function and falls in individuals with multiple sclerosis.Evaluation of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines.Associations Between Bladder Dysfunction and Falls in People with Relapsing-Remitting Multiple SclerosisBarriers experienced by patients with multiple sclerosis in seeking care for lower urinary tract symptoms.The impact of lower urinary tract symptoms on health-related quality of life among patients with multiple sclerosis.Urinary incontinence in multiple sclerosis: prevalence, severity and impact on patients' quality of life.[Therapy of fatigue in multiple sclerosis : A treatment algorithm].
P2860
Q26799341-09B183F4-6538-47D0-BE3F-8379CBF9EB3FQ27012533-4B23E4BC-E43E-4E60-B740-5CFDCF80F78FQ28070040-A15DC264-8A9A-4B6A-8E69-4F8063AD297AQ28073849-180D67FA-3F2F-4A04-AEB3-3C404C19AB6BQ30541961-1D62CF77-795B-41D4-A67F-36ACE513FC64Q34569906-60467887-9987-4E8E-ABD2-E3C60AC88F48Q35114665-D5D5D1E7-F3C7-4202-94B0-713C08366229Q35777277-E2D1F004-1C4F-4CEB-B19E-9C430D254472Q36092241-97B2DD2F-392F-4314-96F2-7D6240356F94Q36235033-0C112E66-4C44-487D-B6F4-26372A8F4FE1Q37158954-B8C49B03-29E3-4296-AB17-A135517360A9Q37317758-A7938B06-9AB4-4455-B84D-6822E51BE866Q37354118-3ABDFD83-4CF6-4935-AE73-A384643073A8Q37442370-77CE0EAE-88F6-430D-B4AC-833E37398093Q37496473-EE923B31-0226-4569-BF9D-B87160B727EBQ37631466-28070B99-1909-4A8C-BA40-9B8F274A1331Q37668542-B2C8AA90-C8DF-4DCE-805D-C4A962C75B41Q38031284-376D61EF-46B0-4F91-96FB-A97B475D2E00Q38231743-323C8159-DFE0-422B-A2FE-42EB9A969E33Q38508246-7F954ACF-8266-4242-9F55-72468C126FEFQ38618854-67F2B334-F309-453E-9245-4B37A4947DC4Q38794193-FEACDDA5-9F27-4A2C-AC16-ECF1C9EE4AB7Q38828531-5D87384C-29EB-4E48-914F-2D6E6B75312AQ39262833-D482BBDE-8279-49BA-8EFB-97D4D6CA29B2Q41469175-CD85482F-72F6-4BF9-B800-3BAC592D8EF3Q46190605-D5C72957-8F60-4223-BFF1-C87516E2C9B4Q46245009-A25A3F07-5014-49F3-8E11-0F31DC3F7F42Q47763770-9671D08D-AE56-4C34-96B9-DA40D5F7F5A4Q52849592-6462B7C8-7C09-42E7-86B7-4077D49068D5
P2860
Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Under treatment of overactive ...... the NARCOMS Patient Registry.
@en
Under treatment of overactive ...... the NARCOMS Patient Registry.
@nl
type
label
Under treatment of overactive ...... the NARCOMS Patient Registry.
@en
Under treatment of overactive ...... the NARCOMS Patient Registry.
@nl
prefLabel
Under treatment of overactive ...... the NARCOMS Patient Registry.
@en
Under treatment of overactive ...... the NARCOMS Patient Registry.
@nl
P1476
Under treatment of overactive ...... the NARCOMS Patient Registry.
@en
P2093
S T Mahajan
P304
P356
10.1016/J.JURO.2009.12.029
P407
P577
2010-02-20T00:00:00Z